Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
CALIDI BIOTHERAPEUTICS INC (CLDI)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$0.68-7.51%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CLDI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital via equity warrants and offerings | A supporting condition in CALIDI BIOTHERAPEUTICS INC's published investment case. The stated target is maintain liquidity with controlled equity issuance. | Under Pressure | excessive dilution or failure to raise needed capital | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making clinical-stage biotech with a speculative growth profile, not an established earnings compounder. The thesis is in a watch state, with low confidence and volatile management execution; recent performance remains below its industry group.
The evidence does not provide a valuation measure or a clear account of market expectations, so whether CLDI is cheap or expensive versus peers cannot be assessed. The snapshot does show weak fundamentals and elevated risk, but it does not establish how much of those concerns is already reflected in the market.
Near term, operating losses and a high risk of another earnings miss remain concerns, though management reduced general and administrative expenses in Q1 and Q2 2026 versus the prior year. Over the multi-year view, the key progress is whether CLDI files the CLD-401 IND application by the end of 2026 and advances its pipeline beyond preclinical work; the September listing-rule notice adds risk.
The thesis depends on timely delivery of the CLD-401 filing and evidence that RedTail pipeline work can advance toward clinical milestones, while expense control continues. Near-term guidance, employment data, and results from sector bellwethers could also affect the operating backdrop, but the snapshot gives no company-specific clinical outcomes.
Over the next 1 to 3 years, CLDI remains a low-confidence, high-risk development story with some cost-control progress but no clinical milestone delivery yet. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Calidi plans to file an IND for CLD-401 in Q4 2026. |
| Intact |
| IND filing is not completed by end of 2026-Q4 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses toward -$4.19M per quarter | Operating losses improved from -$5.77M to -$4.19M in recent quarters. | Intact | operating loss worsens beyond -$4.19M per quarter | Operating income: $-4.15M FY2026-Q2; GAAP. Published target: operating loss <= -$4.19M per quarter. Target period is not explicitly aligned with this observation. Aug 13, 2026-4,150,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-4.80 → $-76.80 · observed estimates
FY2027 revenue: comparable history unavailable.
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-4.80 | Unavailable | 1 / 0 |
| 2026-07-25 | $-4.80 | Unavailable | 1 / 0 |
| 2026-07-26 | $-4.80 | Unavailable | 1 / 0 |
| 2026-07-27 | $-4.80 | Unavailable | 1 / 0 |
| 2026-07-28 | $-4.80 | Unavailable | 1 / 0 |
| 2026-07-29 | $-4.80 | Unavailable | 1 / 0 |
| 2026-07-30 | $-4.80 | Unavailable | 1 / 0 |
| 2026-07-31 | $-4.80 | Unavailable | 1 / 0 |
| 2026-08-01 | $-4.80 | Unavailable | 1 / 0 |
| 2026-08-02 | $-4.80 | Unavailable | 1 / 0 |
| 2026-08-03 | $-4.80 | Unavailable | 1 / 0 |
| 2026-08-04 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-05 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-06 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-07 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-08 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-09 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-10 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-11 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-12 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-13 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-14 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-15 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-16 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-17 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-18 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-19 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-20 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-21 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-22 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-23 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-24 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-25 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-26 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-27 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-28 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-29 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-30 | $-76.80 | Unavailable | 1 / 0 |
| 2026-08-31 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-01 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-02 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-03 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-04 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-05 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-06 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-07 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-08 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-09 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-10 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-11 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-12 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-13 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-14 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-15 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-16 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-17 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-18 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-19 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-20 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-21 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-22 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-23 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-24 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-25 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-26 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-27 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-28 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-29 | $-76.80 | Unavailable | 1 / 0 |
| 2026-09-30 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-01 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-02 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-03 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-04 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-05 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-06 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-07 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-08 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-09 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-10 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-11 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-12 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-13 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-14 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-15 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-16 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-17 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-18 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-19 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-20 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-21 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-22 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-23 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-24 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-25 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-26 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-27 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-28 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-29 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-30 | $-76.80 | Unavailable | 1 / 0 |
| 2026-10-31 | $-76.80 | Unavailable | 1 / 0 |
| 2026-11-01 | $-76.80 | Unavailable | 1 / 0 |
| 2026-11-02 | $-76.80 | Unavailable | 1 / 0 |
| 2026-11-03 | $-76.80 | Unavailable | 1 / 0 |
| 2026-11-04 | $-76.80 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.